Published by Benjamin Chiou on 28th August 2024
(Sharecast News) - Shore Capital has reiterated its 'buy' rating on GSK after the biopharma giant's latest update about its ongoing Zantac litigation, saying that the stock's valuation is still undemanding compared with the wider market.
URL: http://www.digitallook.com/dl/news/story/34518036/...